Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Issued
Ratios

TriSalus Life Sciences (TLSIW) Cost of Revenue (2022 - 2025)

TriSalus Life Sciences' Cost of Revenue history spans 4 years, with the latest figure at $8.0 million for Q4 2025.

  • For Q4 2025, Cost of Revenue fell 65.26% year-over-year to $8.0 million; the TTM value through Dec 2025 reached $23.5 million, down 24.12%, while the annual FY2025 figure was $28.7 million, 11.11% up from the prior year.
  • Cost of Revenue reached $8.0 million in Q4 2025 per TLSIW's latest filing, up from $6.8 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $23.0 million in Q4 2024 to a low of $589000.0 in Q3 2023.
  • Average Cost of Revenue over 4 years is $6.3 million, with a median of $4.6 million recorded in 2023.
  • Peak YoY movement for Cost of Revenue: tumbled 80.56% in 2023, then skyrocketed 677.72% in 2024.
  • A 4-year view of Cost of Revenue shows it stood at $11.3 million in 2022, then surged by 32.89% to $15.0 million in 2023, then surged by 52.9% to $23.0 million in 2024, then tumbled by 65.26% to $8.0 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Cost of Revenue are $8.0 million (Q4 2025), $6.8 million (Q3 2025), and $7.2 million (Q2 2025).